Guardant Health Inc

NASDAQ:GH   3:59:50 PM EDT
119.91
-0.29 (-0.24%)
Products

FDA Approved Rybrevant As First Treatment For Adult Patients With Non-Small Cell Lung Cancer

Published: 05/21/2021 16:41 GMT
Guardant Health Inc (GH) - FDA Approves First Targeted Therapy for Subset of Non-small Cell Lung Cancer.
Approved Rybrevant (amivantamab-vmjw) As First Treatment for Adult Patients With Non-small Cell Lung Cancer.
Granted Approval of Rybrevant to Janssen Pharmaceutical Companies of Johnson & Johnson.
Also Approved Guardant360 Cdx (guardant Health Inc.) As a Companion Diagnostic for Rybrevant Today.